PM14 Administered Intravenously to Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2023-02-13
Target enrollment:
Participant gender:
Summary
Despite recent advances in the treatment of solid tumors in general, advanced (metastatic)
disease remains mostly incurable and there is an urgent need to develop new therapeutic
options for these patients, particularly investigational drugs with novel mechanisms of
action. The investigation of new combination regimens of non-crossresistant agents with
acceptable-and not completely overlapping-toxicities has been a major way to improve response
rate and outcome of patients with advanced solid tumors.